Aytu Biopharma, Inc. revenue by segment AYTU

Annual Quarterly

Aytu Biopharma, Inc. splits its revenue into 5 lines in its filings. The largest line in Q4 of fiscal 2026, the quarter ended Jun 30, 2026 was ADHD Portfolio at $10.4 million, 64% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	Q4 FY2026 Jun 30, 2026	Q3 FY2026 Mar 31, 2026	Q2 FY2026 Dec 31, 2025	Q1 FY2026 Sep 30, 2025	Q4 FY2025 Jun 30, 2025	Q3 FY2025 Mar 31, 2025	Q2 FY2025 Dec 31, 2024	Q1 FY2025 Sep 30, 2024
Revenue	16	12	15	14	15	18	16	17
Adhd Portfolio	—	—	—	—	—	15 share 83.4%	—	—
ADHD Portfolio	10 -21.0% share 64.3%	9 share 73.3%	13 -4.3% share 87.1%	13 -13.8% share 94.7%	13 share 86.6%	—	14 share 85.2%	15 share 92.1%
EXXUA Portfolio	4 share 24.4%	2 share 19.3%	0 share 1.6%	—	—	—	—	—
The Pediatric Portfolio	2 -10.3% share 11.2%	1 -69.9% share 7.4%	2 -29.6% share 11.1%	1 -44.7% share 5.1%	2 share 13.3%	3 share 16.6%	2 share 14.8%	1 share 7.8%
Product And Service Other	0 -100.0% share 0.0%	—	0 +280.0% share 0.1%	0 +0.0% share 0.1%	0 share 0.1%	0 share 0.0%	0 share 0.0%	0 share 0.1%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: AYTU (Nasdaq)
Fiscal year ends: June 30
Incorporated in: DE
Headquarters: Denver, CO
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1385818
Former names: AYTU BIOSCIENCE, INC (until Mar 22, 2021); Rosewind CORP (until Jun 8, 2015)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.